Pharmacoscopy for Patients With Refractory Primary Brain Tumors
NCT: NCT06804655 · NOT_YET_RECRUITING
Brief Summary
Advanced technology of ex vivo drug profiling referred to as pharmacoscopy may allow to identify novel drugs for the treatment of glioblastoma and other refractory brain tumors at an individual patient level. This personalized therapeutic approach was developed and validated in pre-clinical glioma models. With the current research proposal, we seek to establish feasibility for a clinical interventional trial for patients with refractory primary brain tumors that is based on pharmacoscopy-guided selection of treatment. The study is supported by an unrestricted grant from Anti Cancer Fund.
Frequently Asked Questions
What is Pharmacoscopy for Patients With Refractory Primary Brain Tumors?
Pharmacoscopy for Patients With Refractory Primary Brain Tumors is a clinical trial registered under NCT06804655. Current status: NOT_YET_RECRUITING.
What is the status of NCT06804655?
The current status of NCT06804655 (Pharmacoscopy for Patients With Refractory Primary Brain Tumors) is: NOT_YET_RECRUITING.
When did Pharmacoscopy for Patients With Refractory Primary Brain Tumors start?
Pharmacoscopy for Patients With Refractory Primary Brain Tumors started on 2026-06-01.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.